Skip to content
Precision for Medicine
Press Release

FDA Veteran Paz Vellanki, MD, joins Precision to become one of 3 ex-FDA oncology leaders supporting clients

Cell-Based Assays and Imaging

Cell-based assays in both 2D and 3D formats across a broad range of human primary cell types
Our assays have provided data supporting a range of different therapeutic indications from diabetes to fibrosis and oncology, but our primary focus remains in anti-inflammatory and autoimmune research. Our customized approach develops fit-for-purpose assays to the specific needs of your program. In addition to assay development, our breadth of analytical platforms enables us to deliver a comprehensive range of assay endpoints, including mediator/cytokine release, changes in gene expression, ICC, and high content cellular imaging.

Cell-Based assays customized to your program

Example Cell Types Used for Assay Development


  • Blood cells: PBMCs, monocytes, lymphocytes, neutrophils, monocyte-derived macrophages
  • Skin cells: fibroblasts
  • Lung cells: bronchial epithelial cells, alveolar macrophages, alveolar type II cells, smooth muscle cells, tumor epithelial cells, cancer-associated fibroblasts
  • Liver cells: hepatocytes, Kupffer cells, stellate cells
  • Other cell types:  pancreatic islets, synovial fibroblasts

Culture Formats


  • 2D
    • multiwell plates
    • transwells
  • 3D
    • air-liquid interface
    • matrix-based and matrix free
    • simple or co-culture

Cell-Based Assay and Endpoint Types


  • Cytokine-mediator release
  • Cell viability/proliferation
  • Apoptosis
  • Changes in gene expression
  • Enzyme activity/release
  • Barrier permeability
  • Cell migration
  • ICC
  • Multiplex immunofluorescence/high content cellular imaging

CELL TYPE(S)ASSAY EXAMPLES

Whole blood

Inhibition of LPS stimulated TNFα and IL-6 release

Stimulation (PHA) and inhibition (CsA) of cell proliferation

PBMCs

Inhibition of OKT3 (CD3) stimulated IL-2 and IFNγ release

Inhibition of CD3:CD28 stimulated TNFα release

Monocytes & Monocyte-derived Macrophages

Inhibition of LPS stimulated TNFα release

Lymphocytes

Inhibition of OKT3 (CD3) stimulated IL-2 release

Neutrophils

Transmigration (+HUVEC)

Superoxide release

HUVECs

Inhibition of thrombin stimulated IL-8 and MCP-1 release

Hepatocytes

Inhibition of TNFα stimulated IL-6 and IL-8 release CYP induction (mRNA)

Stellates

TGF-β1-induced changes in fibrogenic gene expression and collagen deposition

Alveolar macrophages

Inhibition of LPS stimulated TNFα release

Synovial fibroblasts (RA)

Validated assay for screening novel anti-TNFα therapeutic antibodies (biosimilars)

Case study: bioassay validation supporting EMA marketing authorization application

Details:

  • 2D assay
  • Synovial fibroblasts from rheumatoid arthritis donors

Assay development included:

  • Reference standard inhibitor
  • Titration of stimulus
  • Selection of sentinel marker
  • Formulation effect

Assay validation included:

  • Linearity and range
  • Relative potency
  • Parallelism
  • Specificity
  • Precisionintra-/interassay
  • Biosimilar screen

Precision also performed a biosimilar screen comparing relative potency vs Humira.


Results

1268-IL-6-RA-syn-fibs-2

Related services

  • Explore
    lmmunohistochemistry (IHC)
    tissue-slide

    lmmunohistochemistry (IHC)

    End-to-end IHC solutions including kitting, sample logistics, staining via all major platforms, and in-house pathology services.
    Explore
    tissue-slide

    lmmunohistochemistry (IHC)

    End-to-end IHC solutions including kitting, sample logistics, staining via all major platforms, and in-house pathology services.
    Explore
  • Explore
    cytometry

    Flow Cytometry

    Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments.
    Explore

    Flow Cytometry

    Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments.
    Explore
  • Explore
    Multiplex

    Multiplex immunofluorescence (mIF)

    Automated multiplex immunofluorescence services that enable quantitative visualization of up to 9 markers in tissue and liquid biopsies.
    Explore

    Multiplex immunofluorescence (mIF)

    Automated multiplex immunofluorescence services that enable quantitative visualization of up to 9 markers in tissue and liquid biopsies.
    Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Read: Case Study: Rapid Execution of Assay Validation Rescued Global Study Case Study: Rapid Execution of Assay Validation Rescued Global Study

Translational Research - Assays

Case Study: Rapid Execution of Assay Validation Rescued Global Study

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=219184495938, hs_child_table_id=0, hs_updated_at=1786473626295, hs_published_at=1787556699873, description=Christie Bongel is a scientist by training, but her true passion lies in leadership, particularly in building leaders and shaping high-performing, trust-based cultures. She believes that many talented bench scientists are promoted into management roles without formal leadership development and is committed to helping close that gap. While culture and people development may not always appear on a balance sheet, she views them as essential drivers of long-term organizational success. As a leadership-focused operations executive, Christie leads laboratory operations and strategy within a global network, partnering with pharmaceutical and biotechnology organizations to navigate complex oncology challenges. Her work spans translational oncology, clinical trial strategy, and laboratory execution, with a focus on translating scientific and operational complexity into clear, actionable strategies that drive meaningful outcomes., avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/1781614819314.png',altText='Christie Bongel',fileId=219203862915}, lastname=Bongel, hs_initial_published_at=1786473638412, hs_created_by_user_id=65712240, hs_created_at=1786473568408, hs_is_edited=false, hs_deleted_at=0, name=Christie, job=Site Director, slug=christie-bongel, hs_updated_by_user_id=92535535}, second={hs_id=159488778874, hs_child_table_id=0, hs_updated_at=1765824406763, hs_published_at=1787556699873, description=Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Kennon%20Daniels.webp',altText='Kennon Daniels',fileId=165893120790}, linkedin=https://www.linkedin.com/in/kennon-daniels-ph-d-84a90b6, hs_name=, hs_path=, lastname=Daniels, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745105, hs_is_edited=false, hs_deleted_at=0, name=Kennon, position=Vice President, IVD Regulatory Consulting, job=, slug=kennon-daniels, email=, hs_updated_by_user_id=92535535}, third={}})
  • Christie B. avatar

    Christie B.

  • Kennon D. avatar

    Kennon D.

Discover
Read: Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics

Translational Research - Lab Services

Receptor Occupancy in the Era of Multispecific Therapeutics

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1787556699873, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=92535535}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1787556699873, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=92535535}, third={}})
  • Deborah P. avatar

    Deborah P.

  • Jenny Z. avatar

    Jenny Z.

Discover
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

Translational Research

Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1787556699873, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=92535535}, second={}, third={}})
  • Kaylee Mueller avatar

    Kaylee Mueller

Discover